2024
Chapter 6 Clinical diagnosis and evaluation pathway
Lam R, Banini B, Do A, Lim J. Chapter 6 Clinical diagnosis and evaluation pathway. 2024, 77-100. DOI: 10.1016/b978-0-323-99649-5.00003-0.Peer-Reviewed Original Research
2023
Nonalcoholic liver disease: Epidemiology, risk factors, natural history, and management strategies
Agyapong G, Dashti F, Banini B. Nonalcoholic liver disease: Epidemiology, risk factors, natural history, and management strategies. Annals Of The New York Academy Of Sciences 2023, 1526: 16-29. PMID: 37400359, PMCID: PMC10524684, DOI: 10.1111/nyas.15012.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsNonalcoholic fatty liver diseaseNonalcoholic fatty liverLiver diseaseRisk factorsCommon chronic liver diseaseEnd-stage liver diseaseNatural historyNAFLD risk factorsChronic liver diseaseFatty liver diseaseCurrent management strategiesClinicopathologic spectrumLiver transplantationNonalcoholic steatohepatitisProgressive fibrosisFatty liverHepatocellular cancerLeading indicationDiseaseUnited StatesManagement strategiesCirrhosisSteatohepatitisTransplantationFibrosis
2021
NAFLD-related HCC
Banini BA, Sanyal AJ. NAFLD-related HCC. Advances In Cancer Research 2021, 149: 143-169. PMID: 33579423, DOI: 10.1016/bs.acr.2020.11.001.ChaptersConceptsNonalcoholic fatty liver diseaseHepatocellular carcinomaType 2 diabetes mellitusFatty liver diseaseNumber of patientsDiabetes mellitusMetabolic syndromeLiver diseaseCurrent evidenceMain molecular mechanismsMetabolic perturbationsTwo- toUnites StatesMolecular mechanismsMellitusObesityPatientsCarcinomaGlobal increaseSyndromeDiseaseIncidenceHepatocarcinogenesis
2020
Knockout of sulfatase 2 is associated with decreased steatohepatitis and fibrosis in a mouse model of nonalcoholic fatty liver disease
Kim TH, Banini BA, Asumda FZ, Campbell NA, Hu C, Moser CD, Shire AM, Han S, Ma C, Krishnan A, Mounajjed T, White TA, Gores GJ, LeBrasseur NK, Charlton MR, Roberts LR. Knockout of sulfatase 2 is associated with decreased steatohepatitis and fibrosis in a mouse model of nonalcoholic fatty liver disease. AJP Gastrointestinal And Liver Physiology 2020, 319: g333-g344. PMID: 32683952, PMCID: PMC7509257, DOI: 10.1152/ajpgi.00150.2019.Peer-Reviewed Original ResearchConceptsFast food dietStandard chow dietWT miceDiet-induced steatohepatitisNonalcoholic steatohepatitisSulfatase 2Hepatic fibrosisMouse modelStandard chow diet ad libitumChow diet ad libitumNonalcoholic fatty liver diseaseDiet-induced mouse modelConditions of overnutritionProtein expressionFatty liver diseasePotential therapeutic mechanismWild-type miceDiet ad libitumThreefold increaseLiver diseaseChow dietKO miceLiver fibrosisSteatohepatitisMurine model
2019
Haptoglobin 2 Allele is Associated With Histologic Response to Vitamin E in Subjects With Nonalcoholic Steatohepatitis
Banini BA, Cazanave SC, Yates KP, Asgharpour A, Vincent R, Mirshahi F, Le P, Contos MJ, Tonascia J, Chalasani NP, Kowdley KV, McCullough AJ, Behling CA, Schwimmer JB, Lavine JE, Sanyal AJ. Haptoglobin 2 Allele is Associated With Histologic Response to Vitamin E in Subjects With Nonalcoholic Steatohepatitis. Journal Of Clinical Gastroenterology 2019, 53: 750-758. PMID: 30586008, PMCID: PMC6588507, DOI: 10.1097/mcg.0000000000001142.Peer-Reviewed Original ResearchConceptsNonalcoholic fatty liver disease activity scoreNonalcoholic steatohepatitisLiver enzymesHistologic responseHp genotypeVitamin ENonalcoholic fatty liver diseaseResolution of steatohepatitisSignificant histologic improvementDisease Activity ScoreFatty liver diseaseHp 1 alleleRegression analysisEffect of VitEHaptoglobin 2 alleleDifferential treatment effectsGreater histologicCardiovascular outcomesHistologic improvementDiabetes mellitusLaboratory markersActivity scoreLiver diseaseHistologic featuresFibrosis stageVitamin E in Nonalcoholic Fatty Liver Disease
Banini B, Sanyal A. Vitamin E in Nonalcoholic Fatty Liver Disease. Nutrition And Health 2019, 311-323. DOI: 10.1007/978-3-030-05315-4_23.ChaptersNonalcoholic fatty liver diseaseVitamin E supplementationChronic liver diseaseFatty liver diseaseNonalcoholic steatohepatitisLiver diseaseE supplementationVitamin ESubtype of NAFLDAnnual direct medical costsChronic viral hepatitisAlcoholic liver diseaseClinical practice guidelinesDirect medical costsLong-term useNAFLD patientsLabel treatmentViral hepatitisPharmacological therapyComplex pathogenesisHistological featuresLiver fibrosisClinical trialsLeading causeClinical studies
2017
The Transcriptomic Signature Of Disease Development And Progression Of Nonalcoholic Fatty Liver Disease
Cazanave S, Podtelezhnikov A, Jensen K, Seneshaw M, Kumar DP, Min HK, Santhekadur PK, Banini B, Mauro AG, M. Oseini A, Vincent R, Tanis KQ, Webber AL, Wang L, Bedossa P, Mirshahi F, Sanyal AJ. The Transcriptomic Signature Of Disease Development And Progression Of Nonalcoholic Fatty Liver Disease. Scientific Reports 2017, 7: 17193. PMID: 29222421, PMCID: PMC5722878, DOI: 10.1038/s41598-017-17370-6.Peer-Reviewed Original ResearchConceptsNonalcoholic fatty liver diseaseFatty liver diseaseAdvanced fibrosisLiver diseaseMacrophage activationPathway activationHepatic stellate cell activationFatty liver developmentStellate cell activationOxidative stress pathwaysCell deathAdvanced diseaseMetabolic pathway activationChow dietFatty liverEarly fibrosisFibrogenic pathwaysCell stressSuch miceAnimal modelsCell activationFibrosisMetabolic perturbationsDiseaseOxidative stressCurrent and future pharmacologic treatment of nonalcoholic steatohepatitis
Banini BA, Sanyal AJ. Current and future pharmacologic treatment of nonalcoholic steatohepatitis. Current Opinion In Gastroenterology 2017, 33: 134-141. PMID: 28346237, PMCID: PMC5491795, DOI: 10.1097/mog.0000000000000356.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsNonalcoholic fatty liver diseaseEnd-stage liver diseaseNonalcoholic steatohepatitisLiver diseaseTrend of NAFLDChemokine receptor type 2Future pharmacologic treatmentsCornerstone of therapyStage liver diseaseFatty liver diseasePeroxisome proliferator activator receptorProgression of fibrosisAnti-inflammatory agentsDietary caloric restrictionGlucagon-like peptide 1 pathwayReceptor type 2Liver histologyMetabolic endotoxemiaPharmacologic treatmentTherapeutic optionsHepatocellular cancerAntifibrotic agentsIntestinal microbiomeAggressive formPharmacologic target
2016
Molecular mechanisms of lipotoxicity and glucotoxicity in nonalcoholic fatty liver disease
Mota M, Banini BA, Cazanave SC, Sanyal AJ. Molecular mechanisms of lipotoxicity and glucotoxicity in nonalcoholic fatty liver disease. Metabolism 2016, 65: 1049-1061. PMID: 26997538, PMCID: PMC4931958, DOI: 10.1016/j.metabol.2016.02.014.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsCCAAT/enhancer-binding homologous proteinNonalcoholic fatty liver diseasePKR-like ER kinaseFatty liver diseaseP53 upregulated modulatorEndoplasmic reticulum stressGlucose intoleranceHepatocellular injuryPharmacological therapyLiver diseaseMetabolic derangementsInsulin resistanceHepatocyte injuryLipotoxic stateC-Jun NH2-terminal kinase 1Exposure of hepatocytesHigh fructoseProtective roleEnergy homeostasisUpregulated modulatorGlucose dietLipotoxicityMitochondrial impairmentOxidative stressReticulum stressNonalcoholic Fatty Liver Disease: Epidemiology, Pathogenesis, Natural History, Diagnosis, and Current Treatment Options
Banini BA, Sanyal AJ. Nonalcoholic Fatty Liver Disease: Epidemiology, Pathogenesis, Natural History, Diagnosis, and Current Treatment Options. Clinical Medicine Insights Therapeutics 2016, 8: cmt.s18885. PMID: 28670148, PMCID: PMC5491796, DOI: 10.4137/cmt.s18885.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsNonalcoholic fatty liver diseaseLiver diseaseManagement of NAFLDPathogenesis of NAFLDAdvanced phase clinical trialsLiver-related outcomesCornerstone of treatmentFirst-line therapyHigh-risk patientsChronic liver diseaseFatty liver diseaseCurrent treatment optionsHepatic manifestationNAFLD patientsMetabolic syndromeMajor etiologyInsulin resistancePharmacologic interventionsTreatment optionsClinical evaluationClinical trialsHigh riskVitamin ENatural historyPatients